Participated · Series C · Jun 2026

PhysicsX offers an AI-based engineering platform that predicts physical behavior in seconds rather than hours or days, enabling engineers to test many more design variations. Its platform is used across aerospace and defense, semiconductors, industrial machinery, automotive, energy and materials. The company plans to expand its platform capabilities, develop larger pre-trained "Large Physics Models," and grow its geographic presence including the U.S. and a new office in Singapore. Recent financing will fund that expansion and product development. Financially, PhysicsX reported rapid commercial momentum: it doubled recognized revenue and tripled booked revenue in the past year while more than doubling its customer count. The company has grown its team to over 300 employees in the last 12 months.

Led · Equity · Jul 2018

EndoGastric Solutions is a Redmond, Washington–based medical device company focused on incisionless surgical technologies for GERD, notably the EsophyX device and the TIF 2.0 procedure. The company positions TIF 2.0 as a safe and effective alternative to surgery, citing more than 140 peer‑reviewed publications and outcomes showing many patients can eliminate daily medications for up to five years. Over 35,000 TIF 2.0 procedures have been performed worldwide, and EGS emphasizes an exemplary safety profile. EGS closed an $18M financing to further drive growth and broaden commercialization of the TIF 2.0 procedure. The financing announcement coincided with a leadership transition: Darin Hammers was appointed President and CEO, replacing Skip Baldino, who will remain a strategic advisor. Management says the new capital will provide added fuel to accelerate the company’s commercial evolution and adoption among physician partners and patients. EndoGastric Solutions develops a minimally invasive treatment for gastroesophageal reflux disease (GERD) using its TIF 2.0 procedure and a proprietary device that corrects the root cause of reflux without surgery. The company reports having performed the procedure on 22,000 patients to date. It aims to expand the reach of its non‑surgical option to capture a larger portion of the GERD market. Financially, EndoGastric recently closed a $45M Series I financing and has raised about $251M since launching in 2003. Company leadership says the new capital establishes a strong financial foundation to pursue significant growth and long‑term commercial viability. EndoGastric Solutions develops and commercializes innovative, evidence-based, incisionless procedural therapy for gastroesophageal reflux disease (GERD). Its core offering is the TIF® procedure, which the company is commercializing to physician customers. The company plans to use new financing to continue commercial expansion of the TIF® procedure and to support its physician customer base. It also intends to invest in sustaining engineering initiatives aimed at optimizing gross margin. The company is led by President and CEO Skip Baldino. GERD is a chronic condition in which the gastroesophageal valve allows gastric contents to reflux into the esophagus, causing heartburn and potential injury to the esophageal lining. EndoGastric Solutions (EGS) is a Redmond, Washington–based medical device company focused on incisionless treatment of GERD via its Transoral Incisionless Fundoplication (TIF) procedure and EsophyX devices. The company markets EsophyX technology—cleared by the FDA in 2007 and updated with the EsophyX Z in 2015—to reconstruct the gastroesophageal valve and reduce reflux. EGS reports more than 17,000 TIF patients treated worldwide since clearance and cites over 50 peer‑review papers documenting outcomes on more than 800 unique study patients. Recent changes in coding and payment—CPT Code 43210 and APC 5331 for TIF procedures effective January 1, 2016—aim to improve patient access and reimbursement. EGS says it will use new financing to begin broad‑scale commercialization and to fund R&D on next‑generation products used in the TIF procedure. The company positions TIF as a minimally invasive alternative that can reduce long‑term PPI use for chronic GERD sufferers. EndoGastric Solutions develops products and procedures that combine gastroenterology and surgery to address unmet needs in gastrointestinal diseases. Its core product, the EsophyX device, was FDA cleared in 2007 and is commercially available in the United States. The EsophyX device is inserted transorally with visual guidance from an endoscope and is used in the TIF procedure to reconstruct the gastroesophageal valve, restoring its competency and reestablishing the barrier to reflux. The company, led by President and CEO Skip Baldino, intends to use newly raised funds to support publishing data from three randomized trials, bring new products to market, and establish clear reimbursement for its technology. Financially, the company completed a $30M Series G financing to support these plans. The article does not disclose operating metrics such as revenue or user counts.

Participated · Debt Financing · Feb 2016

Healthsense deploys sensors and algorithms to establish activity baselines and notify caregivers when a patient’s behavior diverges, enabling early interventions to avoid hospitalizations. The company operates its own data centers and currently has about 23,000 people on its system. CEO A.R. Weiler said the business will use new funding to support expansion of its remote monitoring program this year. Healthsense plans a series of announcements, including release of third‑party clinical validation study results and details on new partnerships. Leadership experience at organizations such as Optum and Virgin HealthMiles is noted through CEO Weiler. The company has raised $34.1 million to date and is based in Minnesota. Healthsense, based in Mendota Heights, MN, provides tech-enabled care solutions for the senior care continuum. It offers wireless care solutions including remote monitoring, emergency response and wellness management systems. The company has deployed several pilot programs within the last year with partners such as Humana Cares/Senior Bridge and Fallon Health. Led by President and CEO A.R. Weiler, Healthsense focuses on supporting senior-care operations across the continuum. In August 2014 Healthsense raised $10M in financing. The company intends to use the funds to continue to grow operations. Healthsense is a provider of next-generation remote monitoring solutions for the senior care market. Its core product is the eNeighbor passive monitoring and analytics technology that enables proactive detection of emerging health concerns and automatic alerts for events such as falls. The platform combines remote monitoring, emergency response, and wellness management to help seniors remain independent, reduce costs, and enhance caregiver and senior experiences. Built on a Wi‑Fi platform, Healthsense’s products are scalable and designed to enable flexible technology-enabled care models for communities and home-based care organizations. The company plans to focus on enhancing care models to advance adoption of remote monitoring in health management and to extend the reach of its platform throughout senior living communities and homes across the United States. Healthsense recently closed an additional $7 million Series D financing to support that expansion. Healthsense offers wireless sensors, nurse call systems and algorithmically-enabled remote monitoring solutions aimed at seniors and people living at home. Its flagship product, the eNeighbor® system, uses a series of wireless sensors placed throughout a residence to capture activities of daily living and automatically call for help if it detects a possible problem. The eNeighbor system was developed under the direction of the National Institute on Aging (NIA) and DARPA. Since introducing its first commercial product in 2006, Healthsense has emerged as a leader in Wi‑Fi sensors and remote monitoring solutions. The company is using new growth capital financing to accelerate sales and marketing and to expand its platform into new markets. The funding amount was undisclosed.

Participated · Series B · Jun 2013

Minimally Invasive Devices (MID) develops FloShield, a tool that prevents laparoscope fogging and contamination by actively protecting and flushing the lens during surgery. The technology eliminates the need to remove the laparoscope for cleaning or defogging, maintaining surgical flow. FloShield protects against condensation, smoke and debris and can flush the lens if it becomes dirty. The product is sold in the US and in 10 countries overseas. MID was founded by laparoscopic surgeon Dr. Wayne Poll and is based in Columbus, Ohio. The company has taken on outside financing to support working capital and continued growth. Minimally Invasive Devices, Inc. develops and manufactures the FloShield™ laparoscopic vision system, a device that attaches to modern HD vision systems to prevent obscuration of the optics and avoid interruption during surgery. The company is led by founder and CEO Wayne Poll and is based in Columbus, Ohio. It raised an additional $2.5M in Series B financing to support its commercial and clinical efforts. The funds are intended for sales and marketing, clinical studies, generation of outcomes data and additional product development. Prior investors Canaan Partners and Charter Life Sciences had previously invested $9M. The company’s product enables laparoscopic procedures to continue without removing the scope for cleaning. Minimally Invasive Devices produces the FDA‑approved FloShield™ laparoscopic vision system, which attaches to HD camera systems and uses an air curtain to form an invisible protective barrier over the lens. The system is augmented by Flo‑X, a biocompatible surfactant designed to flush the lens inside the body if needed. The company says its products allow surgeons to operate without loss of vision and without lens removal. Minimally Invasive Devices intends to use new capital to establish a direct sales unit, expand manufacturing operations, develop complementary products and generate additional data to support system efficacy. The company is led by founder and CEO Wayne Poll, M.D., and is based in Columbus, Ohio. Minimally Invasive Devices develops surgical products to improve laparoscopic visibility, led by its FloShield device that prevents liquid from obstructing a laparoscope tip. The company is preparing a next-generation FloShield, an access system for the product, and a compatible liquid cleaning solution. MID has a distribution deal with CareFusion and is seeking a European distributor, and hopes to receive regulatory approval to sell FloShield in the EU around mid-2011. The latest funding will support these product launches and hiring (the company currently has 10 employees and plans to add another sales support worker). MID has refocused away from a previously planned kidney stone removal tool to concentrate on laparoscopic surgery products to increase acquisition appeal. Financially, the company raised $1.35 million last year for earlier development, has raised more than $1.5 million in the current equity round, and has raised about $7 million since its 2007 founding.

Participated · Equity · Nov 2012

Ambit Biosciences is a San Diego-based biopharmaceutical company focused on developing small-molecule kinase inhibitors for cancer and inflammatory diseases. Its lead candidate is quizartinib (AC220), an oral FLT3 inhibitor currently in clinical trials for relapsed/refractory and treatment‑naive AML. Quizartinib is being developed in collaboration with Astellas Pharma under a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors. Ambit's clinical pipeline also includes AC430, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva, and its preclinical portfolio includes a proprietary CSF1R inhibitor. The company plans to use proceeds from a new $50M financing (the first $25M tranche has closed) to continue advancing quizartinib. Michael Martino serves as President and CEO. Ambit Biosciences focuses on discovery and development of small-molecule kinase inhibitors, with a clinical pipeline that includes AC220, AC430, and AC480 and preclinical candidates such as CEP-32496. Its lead candidate, AC220, is a potent, selective, orally bioavailable FLT3 inhibitor being developed in collaboration with Astellas Pharma and is in a Phase 2 pivotal trial for relapsed/refractory AML with FLT3 ITD mutations. AC430 is an oral JAK2 inhibitor and AC480 is a pan-HER inhibitor, both in Phase 1 trials. The company also has partnered or licensed assets (CEP-32496 licensed to Cephalon) and describes an approach to optimizing and selecting potential new drugs. Ambit is privately held and raised new capital in this financing to continue clinical development across its clinical assets. The company announced that the financing provided sufficient funding to pursue its strategy and enabled it to withdraw plans for an initial public offering. Ambit Biosciences is a San Diego–based developer of small‑molecule profiling tools used in biopharmaceutical development. The company reported an ongoing debt financing and has disclosed $6.5M raised to date in that round. According to the firm's filing it is raising up to $19.7M in debt, including warrants. Details on the debt financing (investor identities and specific terms) were not released in the filing. Ambit has previously raised over $105M in venture funding. Historical investors named in filings include Apposite Capital, MedImmune, OrbiMed, Radius Ventures, NovaQuest, Horizon Technology Finance, Avalon Ventures, Perseus‑Soros Biopharmaceutical Fund, Forward Ventures, Roche Venture Fund, Lumira Capital, GIMV, Genechem Management, and Bristol‑Myers Squibb. Ambit Biosciences is a San Diego-based biotechnology company focused on developing small-molecule kinase inhibitors for the treatment of cancer. Its core product strategy centers on advancing small-molecule kinase inhibitor candidates through development. The company announced a $49.3M Series D equity financing to help advance its product pipeline. The financing syndicate includes strategic life-science investors and venture funds. Ambit intends to apply the proceeds toward progressing its pipeline candidates and clinical efforts. The article does not disclose operating metrics such as revenue or user figures.